1-20 of 60 < first | prev | | last >
  • The Executive Guide to Contracts & Chargeback Management

    When it comes to un-validated chargebacks the stakes are and can quickly erode the manufacturer's margins and quickly amount to significant financial loss. Time pressures, transaction volume, and requirements for data accuracy combined to make managing chargebacks a significant challenge for many Life Sciences companies. But by automating the chargeback validation process, and having up-to-date information on contracts, prices, and memberships, life sciences companies ensure that only valid credits are authorized and processed, reducing both the amount of labor they expend, and the volume and amount of their unauthorized deductions.

    CDC Ross Enterprise
  • Maximizing the Value of Supplier Relationships

    CIO Leadership talks to Jonathan Hughes, of Vantage Partners, about how companies and suppliers can best foster the kinds of relationships with suppliers that deliver sustainable value and competitive advantage.

    CIO Leadership and Vantage Partners
  • Part 1: State of the Industry: A Tefen Series: Operational Excellence in the Life Sciences

    The life sciences industry is under pressure from the decline in the discovery of block-buster products, aggressive strategies from the generic manufacturers, the emergence of competitors from the East, and the global economic downturn. These factors are causing the pharmaceutical, biotech, and medical device companies to rethink the way they operate. Growth is no longer the mantra of the Life Sciences industry, but it is survival and maintaining a competitive advantage. The ability to supply products in the most cost-effective manner through efficiency initiatives has become necessary just to survive. Over the last 5 years, this has led life sciences companies to embark on operational excellence (OpEx) programs, based on lean, six sigma and other improvement methodologies. This paper summarizes research conducted by Tefen Ltd. in 2008-2009 on these OpEx programs, and how they have reshaped the way life sciences companies develop, supply, and even sell their products.

  • Part 3: Learning from the Industry: A Tefen Series: Operational Excellence in the Life Sciences

    Tefen Ltd conducted a study in 2008 & 2009 on 11 life sciences companies, including AstraZeneca, Bayer Schering, GSK Bio, Ipsen, Janssen, Merck Serono, Novartis, Nycomed, Schering Plough, and Wyeth. The research focused on their Operational Excellence (OpEx) programs and is discussed in this three part series. In part one of the study, “The State of the Industry,” Caldwell, Mathew, and O’Donnell discuss how the life sciences industry is being affected by the decline of blockbuster drugs, competition from generic manufacturers and the East, and the economic crisis. “Operational Excellence Programs in the Industry”, part two of this series, explored the benefits of a lean and six sigma approach, and the necessary management to make the program work. The conclusion of the series, “Learning from the Industry,” will explore lessons learned and best practices from the 11 companies researched for this article.

  • Brandjacking Index: Online Risks in Pharmaceutical Market

    Buying drugs online continues to be fraught with fraudsters and continues to be popular because of the high demand for inexpensive medicines. While tracking six different drug brands in July 2009, four of which were patented, MarkMonitor observed continued growth in the online market for pharmaceuticals including high levels of traffic to suspicious online pharmacies and increased numbers of listings for pharmaceuticals on B2B exchange sites.

  • Tales from the Counterfeiting Front: USP’s Drug Quality Matrix

    USP has released an updated version of its matrix tracking public reports of counterfeit and substandard drugs worldwide. The report is more anecdotal than comprehensive—there’s no way to chronicle all incidents—but tells a vivid story of the challenges facing local authorities worldwide in battling counterfeits. Also, read here about how USP and USAID are ramping up their counterefforts.

  • Five Ways to Improve Fiscal Fitness with Rapid Microbial Screening

    Manufacturers have a tendency to overlook quality control when streamlining their operations, and yet microbial testing is one area where tremendous time and cost savings can be realized. Through rapid screening, manufacturers can slash non-value-add time, cut inventory requirements and reduce carrying costs. This white paper, courtesy of Celsis Rapid Detection, outlines how today’s rapid screening systems can provide accurate results in as few as 24 hours—validated and accepted by FDA—and can trim days from the average production cycle.

    Celsis, Inc.
  • Optimizing the Global Manufacturing Network

    How can today's manufacturers best address supply chain problems and how companies can measure their supply and manufacturing network performance? Manufacturing Insights' Simon Ellis provides best practices on how manufacturers can optimize their global networks.

    SAP America
  • Three Scenarios for Reducing Raw Material Inspection Costs: How Can You Cut Costs in the Inspection of Your Raw Materials?

    An independent research firm performed an objective study of the financial returns generated by the use of Ahura Scientific's TruScan, a handheld Raman spectrometer now used by 9 of the top 10 pharma companies. It considered the primary challenges facing the manufacturing and supply chains for these consumer health, pharmaceutical, and consumer packaged goods manufacturers, and developed three scenarios for significant ROI. These cost-saving scenarios are presented here.

    Ahura Scientific, Inc.
  • Accounting for Risk in Your Asset Management Strategy

    A risk-based asset management system will help you appropriately prioritize how you spend time, money and materials fixing the most critical problems, provide the infrastructure for continuous improvement and help you meet your corporate business objectives, including regulatory compliance. This paper offers an overview of the three key elements of an asset management strategy and presents the six steps to building a robust, risk-based asset management program.

    Life Cycle Engineering
  • Environmental Monitoring and Certification in Controlled Environments

    Environmental testing and monitoring programs are essential elements in pharmaceutical and medical device manufacturing. Companies must understand industrial sterilization and contamination control procedures to bring products to market on time and on budget. Steven Wieczorek of Microtest Laboratories reviews the key elements of a best-practice environmental testing program, including sterilization standards, FDA requirements, and the critical factors in maintaining controlled environments.

    Microtest Laboratories
  • Special Report: The Coming of Age of the Indian Pharma Outsourcing Industry

    This report by the Organization of Pharmaceutical Producers of India (OPPI) and Ernst & Young presents trends in the global pharmaceutical industry that are leading to an increase in outsourcing and an assessment of the capabilities and potential for growth of the Indian custom manufacturing and drug discovery and development outsourcing industry.

    Ernst & Young and OPPI
  • Taxanes - Taxol (Paclitaxel) and Taxol B (Cephalomannine)

    This application note describes the measurement of taxanes: Taxol (Paclitaxel) and Taxol B (Cephalomannine). The method has a limit of detection of about 5 ng on column, excellent precison and a dynamic range from ng to ug levels.

    ESA Biosciences, Inc.
  • Rapid Analysis of Antibiotics and Impurities by UHPLC and Corona ultra Detection

    This application note describes the use of the Corona ultra with UHPLC allows for both rapid and sensitive detection of Aminoglycoside antibiotics (e.g., amikacin, tobramycin, and neomycin). This application demonstrates a range of four orders of magnitude and detects potential impurities of these compounds.

    ESA Biosciences, Inc.
  • Simultaneous Measurement of APIs and Counter-ions by UV, CAD and MS

    This application note describes the use of Corona Charged Aerosol Detector in conjunction with UV/Vis and Mass Spectroscopy allows the simultaneous analysis of both the API and counter-ion and permits the determination of organic and inorganic impurities.

    ESA Biosciences, Inc.
  • Benzodiazepines and Degradants

    This application note describes the use of the Charged Aerosol Detection (CAD) for the measurement of benzodiazepines, and illustrates its ability to simultaneously measure low level contaminants and breakdown products. The method has a limit of detection of ~5-10ng on column, shows good precision [%RSD (n=5) 0.6-1.2 (200ng on column), 0.4-0.9 (2μg on column)] and has a dynamic range from ng to μg levels.

    ESA Biosciences, Inc.
1-20 of 60 < first | prev | | last >